Nuvectis Pharma (NVCT) investor relations material

Corporate overview

• June 2026 licensing agreement with Haisco covered ciprocopan (NXP100) and NXP200, a Phase 1b oral paradox-breaker BRAF inhibitor.

• Completed a $115M follow-on offering in July 2026 to support a broad clinical plan.

Ciprocopan (NXP100)

• Once-daily oral Factor B inhibitor; approved in China for treatment-naïve PNH, with the previously treated PNH application pending; safety described as similar to iptacopan.

• In treatment-naïve PNH Phase 3, 59.5% achieved Hgb ≥12 g/dL vs. 8.3% with eculizumab; average Hgb increase was 5.0 vs. 2.2 g/dL at week 24.

• Previously treated PNH study met its primary endpoint: 52.8% achieved Hgb >12 g/dL, with a 35.5% lower 95% CI bound vs. a prespecified 20% threshold.

• IgAN Phase 2 showed UPCR reductions of 33%, 45.3% and 57.7% at weeks 4, 12 and 24; week-24 eGFR change was +2.74 vs. -1.97 mL/min/1.73m² for placebo; Phase 3 ongoing in China.

• Phase 2 lupus nephritis study ongoing in China; additional development opportunities include MG, dry AMD and C3G.

NXP200

• Oral, brain-penetrant paradox-breaker BRAF inhibitor designed to target all BRAF mutation classes; Phase 1b expansion ongoing in China, with Breakthrough Therapy Designation for recurrent or progressive BRAF V600-mutant high-grade glioma.

• Earlier Phase 1 data showed 37% ORR (7/19) in glioma, including one complete response; no DLTs, MTD not reached, and 76% of TRAEs were grade 1.

• New-salt-form pilot data included two confirmed partial responses and two stable-disease cases in colorectal cancer, plus one partial response in papillary thyroid carcinoma.